Received May 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 1 | — | — |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 2 | X023303 | — |
No symptomatic Adverse Events were reported.; received his first dose of RECOMBIVAX HB at 20 years old (2 years ago, exact date unknown). The patient did not receive their second dose until yesterday (04/30/2025); This spontaneous report was received from a healthcare professional (HCP, also reported as "physician assistant") concerning an approximately 22-year-old male patient. His medical history, concurrent conditions, concomitant therapies and drug reactions/allergies were not reported. The patient was previously unvaccinated as a child. On unspecified date in approximately 2023 (reported as "2 years ago"), at 20-year-old, he was vaccinated with the 1st dose of Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB), 1 dosage form (anatomical location, route of administration, lot # and expiration date were not reported). The patient did not receive his 2nd vaccination until 30-Apr-2025 (also reported as "yesterday"), when he was vaccinated with Hepatitis B Vaccine (Recombinant) injection pre-filled syringe (batch/lot number X023303 has been verified to be a valid batch lot number for Hepatitis B Vaccine [Recombinant], expiration date reported and upon internal validation established as 17-May-2026), dose number 2, 1 mL administered by a health professional (anatomical location and route of administration were not provided) (inappropriate schedule of product administration). Both doses were administered as prophylaxis. No symptomatic adverse events were reported (no adverse event). No additional information reported. Lot # is being requested and will be submitted if received.